5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseAlzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-10-08NCT07011745
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-08-26NCT04437511
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDDepressive Disorder, Treatment-Resistant, depressive disorder, mood disorder, psychiatric disorderActive, not recruitingPhase 32026-08-10NCT05711940
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant DepressionDepressive Disorder, Treatment-Resistant, depressive disorder, mood disorder, psychiatric disorderRecruitingNot applicable2026-06-15NCT03887715
An Open Label Study of CM-AT for the Treatment of Children With Autismautism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorderActive, not recruitingPhase 32026-03-18NCT02649959